Nanoparticle delivery of innate immune agonists combined with ...

This two-pronged approach produced potent T cell–driven and type I interferon–mediated tumor regression and long-term survival in preclinical PDAC models.

Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer · Authors.

Nanoparticle delivery of innate immune agonists combines with ...

Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer.

Nanoparticle delivery of innate immune agonists combines ... - bioRxiv

Combining senescence-inducing MEK and CDK4/6 inhibitors with nanoparticle delivery of STING and TLR4 agonists leads to interferon-driven and cytotoxic T cell- ...

Nanoparticle delivery of innate immune agonists combined with ...

Thus, combining localized immune agonist delivery with systemic tumor-targeted therapy can orchestrate a coordinated type I interferon–driven innate and ...

Abstract B035: Nanoparticle delivery of innate immune agonists ...

Thus, combining localized immune agonist delivery with systemic tumor-targeted therapy can synergize to orchestrate a coordinated Type I ...

Nanocarrier design for pathogen-inspired innate immune agonist ...

Pathogen-inspired nanocarriers take lessons from microbes and ferry multiple innate immune agonists to the same target cell; together, they ...

Nanoparticle delivery of innate immune agonists combined with ...

Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci ...

Nanoparticle delivery of innate immune agonists ... - UMass Profiles

Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer.

Wafik S. El-Deiry, MD, PhD, FACP on X: "Nanoparticle delivery of ...

Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer ...

(PDF) Nanoparticle delivery of innate immune agonists combines ...

Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T... ... Pancreatic ductal adenocarcinoma (PDAC) has quickly ...

Combination therapy with immune agonists and senescence ...

Thus, in the current study, Chibaya et al. ... incorporated a lipid-based nanoparticle containing both STING and TLR4 agonists (immuno-NP) into ...

Nanoparticle Delivery of Innate Immune Agonists Combined with ...

[Science Translational Medicine] Researchers investigated an immunotherapy approach combining delivery of stimulator of interferon genes and ...

Nanocarrier design for pathogen-inspired innate immune agonist ...

STING agonist ADU-S100, which showed antitumor efficacy when delivered via intratumoral (i.t.) injection in B16F10 melanoma tumor-bearing C57BL/6 mice, ...

Pancreatic Cancer Tumors in Mice Shrink after Nano Delivery of ...

The solution was to encapsulate the STING and TRL4 agonists in a novel design of lipid-based nanoparticles. The nanoparticles offered several ...

Full article: Enhancing The Efficacy of Innate Immune Agonists

Based on these previous findings, we believe that successful treatment of infectious diseases through immune modulation strategies targeting TLRs may benefit ...

Immunostimulatory nanoparticle incorporating two immune agonists ...

Nanoparticle is loaded with two potent innate immune agonists. •. The ... agonists, with particular emphasis on versatile nano-delivery systems.

Nanomaterial-encapsulated STING agonists for immune modulation ...

Numerous nanoparticles (NPs) are used in cancer therapy to encapsulate and efficiently deliver active pharmaceutical ingredients to tumor sites ...

A nanoadjuvant that dynamically coordinates innate immune stimuli ...

Although conventional innate immune stimuli contribute to immune activation, they induce exhausted immune cells, resulting in suboptimal ...

Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I ...

Here, we report a nanoparticle optimized for systemic administration that combines immune agonists for TLR9, STING, and RIG-I with a melanoma- ...